UR 12947
Latest Information Update: 21 Dec 2001
Price :
$50 *
At a glance
- Originator Uriach
- Class Antiplatelets; Vascular disorder therapies
- Mechanism of Action Fibrinogen receptor antagonists; GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 21 Dec 2001 Discontinued-Preclinical for Thrombosis in Spain (Unknown route)
- 14 Sep 1998 New profile
- 14 Sep 1998 Preclinical development for Thrombosis in Spain (Unknown route)